In HIV-infected patients, therapeutic drug monitoring (TDM) of antiretroviral drugs is recommended in special populations and in specific situations to optimize therapy. Currently, TDM is performed via measurement of drug plasma concentrations; however, dried blood spots (DBS) may offer a patient friendly and cost-effective alternative. Therefore, this proof-of-concept study assessed the feasibility of TDM of antiretroviral drugs using DBS with sampling at home.
Methods
Included patients were instructed to sample three DBS just before drug intake at three consecutive days at home and one DBS sample together with their routine venous sampling. All samples were analysed using liquid chromatography coupled to tandem mass spectrometry. Feasibility was investigated with a questionnaire and via determination of the calculated plasma trough concentrations.
Results
In total, 50 patients (48 male, mean age 50 years [range 29–69]) have been included, of whom most were virologically and immunologically well-controlled. In total, 200 DBS were collected, of which 87.5% were suitable for analysis. The questionnaire showed that most patients (68%) successfully obtained their first DBS and 51% preferred DBS over plasma sampling. Plasma trough concentrations could adequately be determined from DBS.
Conclusions
This proof-of-concept study confirms the feasibility of TDM of antiretroviral drugs using DBS with sampling at home, thereby opening the possibility to obtain trough concentrations at home in populations where venous sampling is difficult.
References
1.
KredoT., van der WaltJ., SiegfriedN., CohenK.Therapeutic drug monitoring of antiretroviral for people with HIV. Cochrane Database Syst Rev2009; 8: CD007268.
2.
EdelbroekP.M., van der HeijdenJ., StolkL.M.L.Dried blood spot methods in therapeutic drug monitoring: methods, assays, and pitfalls. Ther Drug Monit2009; 31: 327–336.
3.
KoalT., BurhenneH., RamlingR.Quantification of antiretroviral drugs in dried blood samples by means of liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom2005; 19: 2995–3001.
4.
ter HeineR., RosingH., van GorpE.C.M.Quantification of protease inhibitors and non-nucleoside reverse transcriptase inhibitors in dried blood spots by liquid chromatography-triple quadrupole mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci2008; 867: 205–212.
5.
ter HeineR., Alderden-LosC.G., RosingH.Fast and simultaneous determination of darunavir and eleven other antiretroviral drugs for therapeutic drug monitoring: method development and validation for the determination of all currently approved HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in human plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry. Rapid Commun Mass Spectrom2007; 21: 2505–2514.
6.
KromdijkW., MulderJ.W., RosingH., SmitP.M., BeijnenJ.H., HuitemaA.D.R.Use of dried blood spots for the determination of plasma concentrations of nevirapine and efavirenz. J Antimicrob Chemother2012; 67: 1211–1216.
7.
CheungC.Y., van der HeijdenJ., HoogtandersK.Dried blood spot measurement: application in tacrolimus monitoring using limited sampling strategy and abbreviated AUC estimation. Transpl Int2008; 21: 140–145.
8.
LethF.V., KappelhoffB.S., JohnsonD.Pharmacokinetic parameters of nevirapine and efavirenz in relation to antiretroviral efficacy. AIDS Res Hum Retroviruses2006; 22: 232–239.
9.
Barrail-TranA., YazdanpanahY., GoldwirtL.Pharmacokinetics of etravirine, raltegravir and darunavir/ ritonavir in treatment experienced patients. AIDS2010; 24: 2581–2583.
10.
MicheliV., RegazziM., DickinsonL.Lopinavir/ ritonavir pharmacokinetics in HIV/HCV-coinfected patients with or without cirrhosis. Ther Drug Monit2008; 30: 306–313.
11.
Schöller-GyüreM., KakudaT.N., SekarV.Pharmacokinetics of darunavir/ritonavir and TMC125 alone and coadministered in HIV-negative volunteers. Antivir Ther2007; 12: 789–796.
12.
RayJ.E., MarriotD., BlochM.T.Therapeutic drug monitoring of atazanavir: surveillance of pharmacotherapy in the clinic. Br J Clin Pharmacol2005; 60: 291–299.
